Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Publication year range
1.
J Microbiol Methods ; 134: 38-45, 2017 03.
Article in English | MEDLINE | ID: mdl-28093212

ABSTRACT

BACKGROUND: Serological investigation of Toxoplasma gondii can answer many questions about toxoplasmosis in human pathology. Along these lines, studies on serum storage in biobanks need to be performed especially in terms of determining the impact of storage on relevance of sera analysis after freezing. This study assessed the impact of long-term sera storage on the stability of anti-Toxoplasma immunoglobulins. MATERIAL AND METHODS: The stability of anti-Toxoplasma IgG and IgM was studied in 244 and 242 sera respectively, stored at -20°C from one month to ten years. ELISA-immunoassay (Vidas®, bioMérieux) was used for initial and post-storage analyses. Linear models for repeated measures and subgroup analyses were performed to assess the effect of storage duration and sample characteristics on immunoglobulins stability. RESULTS: Until ten years, the variability attributed to storage (maximum 8.07% for IgG, 13.17% for IgM) was below the variations inherent to the serological technique and allowed by quality assurance systems (15%). Subgroup analysis reported no variation attributed to sera storage. Serological interpretation was modified for 3 sera (1.2%) tested for IgM, all stored more than seven years. CONCLUSION: Anti-Toxoplasma immunoglobulins can reliably be measured for at least up to six years of storage with no modification of interpretation of toxoplasmosis serologies.


Subject(s)
Antibodies, Protozoan/blood , Cold Temperature , Serologic Tests , Toxoplasma/immunology , Toxoplasmosis/immunology , Antibodies, Protozoan/immunology , Blood Banks , Enzyme-Linked Immunosorbent Assay/methods , Female , Humans , Immunoglobulin G/immunology , Immunoglobulin M/immunology , Quality Control , Time Factors , Toxoplasmosis/blood
2.
J Neurol Sci ; 314(1-2): 120-5, 2012 Mar 15.
Article in English | MEDLINE | ID: mdl-22050950

ABSTRACT

BACKGROUND: Intravenous rt-PA is effective in hyperacute ischemic stroke (HAIS) but is administered only in few patients. OBJECTIVES: To report the thrombolysis rate in our stroke unit using a stroke code (SC) protocol with a prenotification system and to analyze the SC impact on the thrombolysis rate in a systematic review. METHODS: We report, from 2005 to 2009, the intravenous rt-PA rate in our prospective registry of hyperacute strokes suspicions. The systematic review was conducted in searching PubMed and EMBASE for prospective studies reporting thrombolysis rates and their use of a SC. We categorized SC between those with a prenotification by the Emergency Medical Services and those with only an in-hospital SC system. RESULTS: Among the 1450 stroke patients hospitalized in our stroke unit, 349 were admitted via the SC protocol as suspicions of hyperacute strokes. Intravenous rt-PA rates were: 12.9% of the ischemic strokes, 36% of the suspicions of hyperacute strokes and 59.6% of the HAIS. We found 23 studies reporting thrombolysis rates ranging from 10.3% to 58% of HAIS. Ten studies gave data concerning the use of a SC in case of HAIS. Thrombolysis rate was higher in hospitals with a prenotification system (54.7%) compared with both those with no specific organization (18.2%) (OR=5.43, 95% CI: 3.84-7.73) and those with an in-hospital restricted SC (37.9%) (OR=1.97, 95% CI: 1.53-2.54). CONCLUSIONS: Thrombolysis rate of HAIS is improved by a SC, especially when a prenotification system of thrombolysis candidates by Emergency Medical Services to the stroke unit is used.


Subject(s)
Clinical Protocols , Stroke/diagnosis , Stroke/drug therapy , Thrombolytic Therapy/statistics & numerical data , Age Factors , Aged , Brain Ischemia/drug therapy , Drug Utilization , Emergency Medical Services/statistics & numerical data , Female , Fibrinolytic Agents/therapeutic use , France/epidemiology , Hospitals , Humans , Male , Middle Aged , Paris/epidemiology , Patient Care Team , Prospective Studies , Registries , Stroke/epidemiology , Tissue Plasminogen Activator/therapeutic use
3.
Rev Neurol (Paris) ; 166(1): 66-75, 2010 Jan.
Article in French | MEDLINE | ID: mdl-19403149

ABSTRACT

INTRODUCTION: The most frequent neurological complication of Waldenström's macroglobulinemia is IgM-mediated polyneuropathy. Direct tumor cell infiltration of the nervous system is very rare and better known as the "Bing and Neel syndrome". This syndrome relates usually to a meningeal or meningo-myelo-cerebral tumor infiltration. OBSERVATION: A 54-year-old man developed a terminal cauda equina syndrome over several years. MRI disclosed lumbar roots infiltration and lumbar puncture the presence of lymphocytic meningitis with intrathecal synthesis of monoclonal IgM identical to that found in the blood. The bone biopsy revealed a lymphoplasmocytic infiltration consistent with the diagnosis of Waldenström's macroglobulinemia. The final diagnosis was meningeal and lumbar roots infiltration revealing Waldenström's macroglobulinemia. Partial remission was obtained after polychemotherapy with CHOP, rituximab and methotrexate. At the end of the treatment, the patient improved his bladder's control and was able to walk with a stick. DISCUSSION: We reviewed the 35 cases of "Bing and Neel syndrome" we have identified by a PubMed research. The present case report is original by the initial neurological presentation of the disease three years before diagnosis and the successful use of rituximab in the polychemotherapy regimen.


Subject(s)
Central Nervous System Diseases/blood , Nervous System Neoplasms/complications , Waldenstrom Macroglobulinemia/blood , Antibiotics, Antineoplastic/therapeutic use , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Murine-Derived , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biopsy , Bone and Bones/pathology , Central Nervous System Diseases/complications , Central Nervous System Diseases/drug therapy , Combined Modality Therapy , Cyclophosphamide/therapeutic use , Doxorubicin/therapeutic use , Humans , Magnetic Resonance Imaging , Male , Meningitis/complications , Meningitis/pathology , Methotrexate/therapeutic use , Middle Aged , Neoplasm Invasiveness/pathology , Nervous System Neoplasms/blood , Nervous System Neoplasms/drug therapy , Polyradiculopathy/complications , Polyradiculopathy/pathology , Prednisone/therapeutic use , Rituximab , Spinal Nerve Roots/pathology , Syndrome , Vincristine/therapeutic use , Waldenstrom Macroglobulinemia/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL